Stockscreener 앱 받기
7.36
2.51%
0.18
전일 마감가:
$7.18
열려 있는:
$7.16
하루 거래량:
2.13M
Relative Volume:
1.29
시가총액:
$2.26B
수익:
$2.68B
순이익/손실:
$-184.45M
주가수익비율:
-10.82
EPS:
-0.6805
순현금흐름:
$229.23M
1주 성능:
+5.60%
1개월 성능:
-14.62%
6개월 성능:
-13.00%
1년 성능:
+34.80%
1일 변동 폭
$7.01
$7.405
1주일 범위
$6.785
$7.405
52주 변동 폭
$5.18
$9.475
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
명칭
Amneal Pharmaceuticals Inc
전화
908-947-3120
주소
400 Crossing Boulevard, 3rd Floor, Bridgewater
AMRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
7.36 | 2.26B | 2.68B | -184.45M | 229.23M | -0.6805 |
|
ZTS
Zoetis Inc
|
148.67 | 67.28B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.22 | 45.62B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.71 | 45.01B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
13.65 | 15.60B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
284.73 | 12.77B | 2.76B | 1.11B | 898.10M | 22.77 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-24 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-09-06 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2021-04-07 | 재개 | RBC Capital Mkts | Sector Perform |
| 2021-03-08 | 업그레이드 | Goldman | Sell → Buy |
| 2020-12-14 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2020-12-14 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-07-27 | 개시 | Goldman | Sell |
| 2020-05-12 | 업그레이드 | Guggenheim | Sell → Neutral |
| 2019-12-12 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2019-11-12 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2019-11-07 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2019-07-22 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-07-11 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-07-08 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2019-06-11 | 개시 | Barclays | Equal Weight |
| 2019-05-21 | 업그레이드 | Raymond James | Mkt Perform → Strong Buy |
| 2019-03-20 | 개시 | SunTrust | Buy |
| 2019-03-08 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2018-12-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2018-10-16 | 다운그레이드 | SunTrust | Buy → Hold |
| 2018-08-13 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-07-23 | 개시 | Morgan Stanley | Overweight |
| 2018-06-22 | 개시 | B. Riley FBR, Inc. | Buy |
모두보기
Amneal Pharmaceuticals Inc 주식(AMRX)의 최신 뉴스
Even though Amneal Pharmaceuticals (NASDAQ:AMRX) has lost US$78m market cap in last 7 days, shareholders are still up 125% over 5 years - Yahoo Finance
Is Amneal Pharmaceuticals, Inc. (AMRX) the Best Pharma Stock to Buy for Long Term Growth? - Yahoo
Lobbying Update: $60,000 of AMNEAL PHARMACEUTICALS INC. lobbying was just disclosed - Nasdaq
10 Best Pharma Stocks to Buy for Long Term Growth - Insider Monkey
Amneal donates $1.5M this Parkinson’s Awareness Month - NJBIZ
NY AG reaches $270M multistate opioid settlement with Amneal Pharmaceuticals - Class Action Lawsuits
Amneal Donates $1.5 Million to Support Patients During Parkinson’s Awareness Month - BioSpace
Amneal to Report First Quarter 2025 Results on May 2, 2025 - Bluefield Daily Telegraph
Amneal Boruzu Subcutaneous Formulation Launch - Clinical Oncology News
Amneal Earnings Preview: Key Updates Coming May 2 in Q1 2025 Report - Stock Titan
Amneal’s CREXONT improves sleep in Parkinson’s patients By Investing.com - Investing.com South Africa
Amneal's Combination Drug Shows Improved Sleep Quality In Parkinson's Disease Patients - Benzinga
Amneal Announces New Data from Phase 3 Study Showing Significant Improvements in Sleep Quality with CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Parkinson’s Disease - BioSpace
Amneal Announces New Data From Phase 3 Study - MarketScreener
Amneal’s CREXONT improves sleep in Parkinson’s patients - Investing.com
Breakthrough: New Parkinson's Drug Shows Major Sleep Quality Gains in Phase 3 Trial - Stock Titan
Amneal Pharmaceuticals (AMRX) Expands Coverage for Parkinson's D - GuruFocus
Amneal Announces Expanded Coverage for CREXONT® (Carbidopa and Levodopa) to Enhance Access for Parkinson’s Disease Patients in the U.S. - BioSpace
Amneal gets expanded coverage for Parkinson’s disease drug - Seeking Alpha
Amneal Announces Expanded Coverage For Crexont® To Enhance Access For Parkinson'S Disease Patients In The U.S. - MarketScreener
Amneal and Shilpa introduce Boruzu in US for cancer treatment - Yahoo Finance
Amneal Launches BORUZU™, First Ready-to-Use Bortezomib Injection for Multiple Myeloma and Mantle Cell Lymphoma - The Joplin Globe
Amneal Launches BORUZU , First Ready-to-Use Bortezomib Injection for Multiple Myeloma and Mantle Cell Lymphoma - Business Wire
Groundbreaking Cancer Treatment: First Ready-Made Bortezomib Injection Hits Market - Stock Titan
Amneal Achieves Third U.S. Biosimilar Approval with FYLNETRA™ (pegfilgrastim-pbbk) - Business Wire
Myasthenia Gravis Treatment Market Size, Growth Analysis 2031 - openPR
Insiders At Amneal Pharmaceuticals Sold US$48m In Stock, Alluding To Potential Weakness - simplywall.st
Amneal Digs Deeper Into GLP-1 Aspirations Following Metsera’s IPO - insights.citeline.com
Amneal Pharmaceuticals: Shares Still Feel Significantly Undervalued (NASDAQ:AMRX) - Seeking Alpha
Amneal Pharmaceuticals (AMRX) Stock Soars 45% on Success of New Parkinson’s Treatment - Markets Insider
Amneal Pharmaceuticals’ SWOT analysis: generic drug maker’s stock poised for growth By Investing.com - Investing.com South Africa
Amneal Pharmaceuticals’ SWOT analysis: generic drug maker’s stock poised for growth - Investing.com
Amneal at Barclays Healthcare Conference: Growth and Innovation Insights By Investing.com - Investing.com UK
Amneal to Participate at Upcoming March 2025 Investor Conference - BioSpace
Amneal to Participate at Upcoming Investor Conference - WICZ
Amneal Pharmaceuticals EVP Jason Daly sells $792,159 in stock By Investing.com - Investing.com Australia
Amneal Pharmaceuticals EVP Andrew Boyer sells $1.1 million in stock By Investing.com - Investing.com Australia
Insider Exodus: Amneal Pharmaceuticals Executives and Directors Offload Massive Stock Holdings - TipRanks
Amneal Pharmaceuticals EVP Jason Daly sells $792,159 in stock - Investing.com
Amneal Pharmaceuticals CFO Tasos Konidaris sells $891,000 in stock By Investing.com - Investing.com Canada
Teva denied stay in Amneal patent dispute as it appeals to Supreme Court - MLex
Amneal Pharmaceuticals EVP Andrew Boyer sells $1.1 million in stock - Investing.com
Amneal Pharmaceuticals CFO Tasos Konidaris sells $891,000 in stock - Investing.com
Amneal Pharmaceuticals director Alva Emily Peterson sells $712,000 in stock - Investing.com
Amneal Pharmaceuticals Executives and Director Sell Shares - TradingView
Polycystic Ovarian Syndrome Treatment Market Set for USD 4.3 Billion by 2034 as Demand for Personalized Medicine Rises | Exclusive Report by TMR - GlobeNewswire Inc.
Amneal’s Rytary Follow-On Crexont Could Hit $500m In Sales - Insights
Principal Financial Group Inc. Purchases 8,213 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World
Amneal Pharmaceuticals Inc (AMRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.74%
0.80%
자본화:
|
볼륨(24시간):